Savara announced on Wednesday that its experimental therapy met the primary endpoint of a late-stage trial by significantly improving lung function in patients with autoimmune pulmonary alveolar proteinosis (aPAP), a rare disease that impairs breathing.
aPAP is a rare condition that affects fewer than 5,000 people in the United States. It can lead to shortness of breath, lung scarring, and potentially necessitate a lung transplant. Savara’s inhaled therapy, molgramostim, demonstrated efficacy by improving lung capacity, specifically the ability of the lungs to transfer gas from inhaled air to red blood cells in the lung capillaries, compared to a placebo.
As reported by The Economic Times, the trial results indicated that molgramostim was well-tolerated, with adverse event frequencies being similar between the treatment and placebo groups.